Logo

PharmaShots Weekly Snapshot (March 18-22, 2019)

Share this

PharmaShots Weekly Snapshot (March 18-22, 2019)

Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019

Published: March 22, 2019 | Tags: Novartis, Announces, Spin-Off, Alcon, Eye Care, Business, April 9, 2019

Celgene Collaborates with Exscientia for its AI Drug Discovery Platform

Published: March 22, 2019 | Tags: Celgene, Collaborates, Exscientia, AI, Drug Discovery Platform

Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer’s Disease

Published: March 22, 2019 | Tags: Biogen, Eisai, Terminate, P-III, ENGAGE, EMERGE, Study, Alzheimer’s Disease

?Merck Extends its Strategic Collaboration with NGM Biopharmaceuticals

 Published: March 22, 2019 | Tags: Merck, Extends, Development, Commercializing, Agreement, NGM, Novel, Biologic, Therapeutics

?Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives FDA’s Approval for the Treatment of Sleep Disorders

Published: March 22, 2019 | Tags: Jazz Pharmaceuticals, Sunosi, solriamfetol, Receives, FDA, Approval, Treatment, Sleep Disorders

?AbbVie Reports FDA’s Hold on All Clinical Trials Evaluating Venclexta/Venclyxto (venetoclax) for Multiple Myeloma

Published: March 20, 2019 | Tags: AbbVie, Announces, FDA, Hold, Venclexta/Venclyxto, venetoclax, P-III, BELLINI, Study, Multiple Myeloma

Merck KGaA Collaborates with GenScript for the Expansion of Cell and Gene Therapies in China

Published: March 20, 2019 |Tags: Merck KGaA, Collaborates, GenScript, Expand, Cell, Gene Therapies, China

?Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)

Published: March 20, 2019 | Tags: Evotec, GARDP, Collaborates, Develop, Novel, Antibiotics, Antimicrobial Resistance, AMR

Sage Therapeutics’ Zulresso (brexanolone) Receives FDA’s Approval for Postpartum Depression (PPD)

Published: March 20, 2019 | Tags: Sage Therapeutics, Zulresso, brexanolone, Receives, FDA, Approval, Postpartum Depression, PPD

Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer

Published: March 20, 2019 | Tags: Merck KGaA, Pfizer, Terminates, P-III, JAVELIN Ovarian PARP 100, Study, Advanced Ovarian Cancer

?Thea Signs a License Agreement with OliX to Develop RNAi Therapies (OLX301A) for Age-Related Macular Degeneration (AMD)

Published:  March 19, 2019 | Tags: Thea, Signs, License, Agreement, OliX, Develop, RNAi Therapies, OLX301A, Age-Related Macular Degeneration, AMD

Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s Approval for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)  

Published: March 19, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Carboplatin, Etoposide, Receive, FDA, Approval, ES-SCLC

Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate

Published: March 19, 2019 | Tags: Akebia Therapeutics, Reports, Positive, Results, Vadadustat, P-III, J01, J03, Studies, Anemia, Chronic Kidney Disease, CKD, Japan

Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI)

Published: March 19, 2019 | Tags: Baxter, BioMerieux, Collaborates, Develop, Biomarkers, Acute Kidney Injury, AKI

AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58 Study for Type-2 Diabetes (T2D)

Published: March 19, 2019 | Tags: ? AstraZeneca, Reports, Positive, Results, Farxiga, P-III, DECLARE-TIMI 58, Study, Type-2 Diabetes

?Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids

Published: March 18, 2019 | Tags: Cellesce, Signs, License, Agreement, Hubrecht Organoid Technology, HUB, Expansion, Organoids

?Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Published: March 18, 2019 | Tags: Novartis, Reports, Results, Entresto, sacubitril/valsartan, PIONEER-HF, 4-Week, Extension, Study, Systolic Heart Failure

Alcon to Acquire PowerVision for $285M

Published: March 18, 2019 | Tags: Novartis, Alcon, Acquire, PowerVision, $285M

 

BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

Published: March 18, 2019 | Tags: BMS, Reports, Positive, Results, Eliquis, apixaban, P-IV, AUGUSTUS, Study, NVAF/ACS/PCI


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions